Manage Tickers Link Financial Account

Has my stock been accused of fraud?Join over 160k users who know.

Ticker	Price	Change($)	Change(%)	Shares	Volume	Prev Close	Open	Gain($)	Gain(%)

Ticker	Status	Jurisdiction	Filing Date	CP Start	CP End	CP Loss	Deadline

Ticker	Case Name	Status	CP Start	CP End	Deadline	Settlement Amt

Ticker	Name	Date	Analyst Firm	Up/Down	Target ($)	Rating Change	Rating Current

IMV Stock Falls After Interim Data From Lead Candidate In Blood Cancer Subtype

Author: Vandana Singh | February 13, 2023 11:29am

IMV Inc (NASDAQ:IMV) announced preliminary data from the VITALIZE Phase 2B trial evaluating its lead DPX product, maveropepimut-S (MVP-S), in combination with Merck & Co Inc's (NYSE:MRK) Keytruda (pembrolizumab) for relapsed, refractory Diffuse Large B Cell Lymphoma (r/r DLBCL).
Related: IMV's MVP-S Doublet Combo Therapy Shows Encouraging Anti-Tumor Activity
8 Patients with an ECOG score of 0-1 have been enrolled in arm 1 of the study. Of these, six have so far been evaluable for efficacy;
Of these six evaluable patients, three showed confirmed complete responses, one was assessed with a stable disease as the best response, and two were assessed with progressive disease as the best response.
Two patients with a poor level of baseline functionality (ECOG ≥ 2) failed to stay on the study through to the first scan and, therefore, could not be evaluated.
Price Action: IMV shares are down 15.15% at $1.68 on the last check Monday.

Posted In: IMV MRK